<div id="readability-page-1">NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...</div>

NVCR

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>NovoCure (NVCR) 将于 4 月 30 日公布其第一季度财报，市场普遍预期每股收益（EPS）为-0.51 美元，同比下降 64.5%；预计收入为 1.6777 亿美元，同比增加 8.2%。在过去两年中，该公司有 63% 的时间超出每股收益和收入预期</p>

NovoCure Q1 2026 earnings preview

NovoCure

NovoCure 2026 年第一季度财报预览